Launch of Frontline flagship store on Tmall Launch of Frontline flagship store on Tmall Boehringer Ingelheim launches Frontline flagship store on Tmall to sell selling full range of pet parasiticides.
garbage game garbage game Learn more about marine pollution and find out how long it takes for garbage to dissolve in the oceans.
U.S. FDA approves first treatment for generalized pustular psoriasis flares in adults U.S. FDA approves first treatment for generalized pustular psoriasis flares in adults Boehringer Ingelheim announces the U.S. FDA has approved the first treatment for generalized pustular psoriasis (GPP) flares in adults
GPP Interview with Professor Barker GPP Interview with Professor Barker An interview with Prof. Barker about generalized pustular psoriasis, its burden on patients and how patient outcomes can be improved
CHMP_opinion_Nintedanib_SSc-ILD CHMP_opinion_Nintedanib_SSc-ILD Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
Rare Diseases: Rare but not alone Rare Diseases: Rare but not alone We are committed to listen and learn from patients with rare diseases to deliver breakthrough therapies.
Health Equity: No distance is too far Health Equity: No distance is too far India is hosting the G20 summit. The leading theme of the G20 summit emphasizes health equity and sustainability as part of the agenda. How we provide access to healthcare for rural areas in India.
Flood-disaster-in-Germany-donation-from-Boehringer-Ingelheim Flood-disaster-in-Germany-donation-from-Boehringer-Ingelheim Boehringer Ingelheim increases donation for emergency flood relief to EUR 1 million
World Patient Safety Day 2021 World Patient Safety Day 2021 As a sign of support for World Patient Safety Day, Boehringer Ingelheim lights up buildings in orange.
ArisGlobal acquires Boehringer Ingelheim technology ArisGlobal acquires Boehringer Ingelheim technology Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
Mental health: a $1 trillion burden demanding policy action Mental health: a $1 trillion burden demanding policy action Nearly one billion people around the world live with a mental health condition, yet an estimated 70% don’t have access to the help they need.
Boehringer Ingelheim invests in precision cancer treatments Boehringer Ingelheim invests in precision cancer treatments Boehringer Ingelheim Venture Fund invests in Synthetica as part of its commitment to advancing innovative, next-generation cancer therapies
FDA Grants Breakthrough Status to Schizophrenia Treatment FDA Grants Breakthrough Status to Schizophrenia Treatment Boehringer Ingelheim and Click Therapeutics receive FDA Breakthrough Device Designation for schizophrenia prescription digital therapeutic
The power of patient advocacy in cancer care The power of patient advocacy in cancer care Larry, a retired US Navy veteran, and Jeff, UICC President, have more in common than a cancer diagnosis: they share a passion for patient empowerment.
Winners of BVDzero Scholarship Programme Winners of BVDzero Scholarship Programme Boehringer Ingelheim announces winners of BVDzero Scholarship Programme
New vaccine against Bovine Respiratory Disease New vaccine against Bovine Respiratory Disease Boehringer Ingelheim’s Bovalto Respi Intranasal is a new respiratory vaccine for active immunization of cattle against Bovine Respiratory Disease.
New production center for Veterinary Public Health New production center for Veterinary Public Health Boehringer Ingelheim invests more than €200 million to establish a strategic production center for Veterinary Public Health in Lyon, France.
Official partner to Cat Care for Life Official partner to Cat Care for Life Boehringer Ingelheim announces its new partnership with the CatCareforLife program.
GastroGard the first imported equine drug in China GastroGard the first imported equine drug in China GastroGard® approved as the first imported equine drug in China. Boehringer Ingelheim officially starts equine health business in China.
Approval for Aservo EquiHaler equine asthma therapy Approval for Aservo EquiHaler equine asthma therapy Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first equine asthma therapy
Zongertinib positive results non-small cell lung cancer Zongertinib positive results non-small cell lung cancer Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
preserved-heart-failure-treatment-FDA-US-approval preserved-heart-failure-treatment-FDA-US-approval US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
empulse-trial-benefit-acute-heart-failure empulse-trial-benefit-acute-heart-failure Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
preserved-heart-failure-treatment-approval-europe preserved-heart-failure-treatment-approval-europe preserved-heart-failure-treatment-approval-europe